| Name | Title | Contact Details |
|---|
Peace Country Health is a Grande Prairie, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Dayspring Services of Arkansas is a Springdale, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BI Nutraceuticals is a solutions-based botanical manufacturer, custom contract manufacturer, and supplier to the Dietary Supplement, Food & Beverage, Pharmaceutical, Personal Care, and Pet Care Industries. We are the leading manufacturer of whole herb powders and teas, standardized and drug ratio extracts, vitamins, minerals, amino acids, custom blends, drum-to-hopper (D-T-H) formulations, and granular ingredients. BI Nutraceuticals is committed to providing top-quality ingredients, starting even before the raw material comes through the door with our in-depth industry knowledge and distinguished vendor qualification program. The moment we receive the material it undergoes BI`s Protexx HP™ Green Steam™ sterilization, our patented high pressure, low moisture steam sterilization process, and a complete array of tests including Identilok®, our proprietary Species Genus identificaiton technology. The result is a product that meets a quality standard above all others. Quality is our competitive differentiator and the single most important ingredient we sell.
Maven is the largest virtual clinic for women`s and family health, offering continuous, holistic care for fertility, pregnancy, and parenting. Maven`s award-winning digital programs are trusted by leading employers and health plans to reduce costs and drive better health outcomes for both parents and children. Founded in 2014 by CEO Kate Ryder, Maven has been recognized as Fast Company`s #1 Most Innovative Health Company and has supported more than 10 million women and families to date. Maven has raised $92 million in funding from leading investors including Sequoia, Oak HC/FT, and Female Founders Fund.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.